Accuray Appoints Paul Miele as Chief Commercial Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ARAY?
Accuray announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. Most recently, Miele served as Business Unit Leader and General Manager for the Monarch robotic platform at Johnson & Johnson MedTech, where he was recruited to lead a commercial turnaround.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARAY
Wall Street analysts forecast ARAY stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.419
Low
2.00
Averages
2.00
High
2.00
Current: 0.419
Low
2.00
Averages
2.00
High
2.00
About ARAY
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Accuray Appoints New Chief Commercial Officer
- Executive Appointment: Accuray announced the appointment of Paul Miele as Chief Commercial Officer effective April 6, 2026, tasked with leading the global commercial organization to drive transformation and enhance execution, thereby improving market competitiveness.
- Extensive Experience: Miele brings nearly two decades of global commercial leadership experience in the medical technology sector, having previously served as Business Unit Leader at Johnson & Johnson MedTech, where he successfully reversed a revenue decline trend and achieved double-digit annual sales growth.
- Strategic Objectives: As Chief Commercial Officer, Miele will define and execute Accuray's global commercialization strategy across sales, marketing, pricing, and market access, aiming to enhance the company's commercial impact in over 70 countries worldwide.
- Commitment to Innovation: Accuray is dedicated to improving cancer treatment through continuous innovation, and Miele's addition is expected to further drive growth in systems and services sales, particularly in providing value-added solutions to customers.
See More
Accuray Appoints New Chief Commercial Officer
- Executive Appointment: Accuray announced the appointment of Paul Miele as Chief Commercial Officer effective April 6, 2026, tasked with leading the global commercial organization to drive transformation and enhance execution, thereby improving overall commercial performance.
- Extensive Experience: Miele brings nearly two decades of global commercial leadership experience in medical technology, having successfully reversed revenue declines and achieved double-digit annual sales growth as Business Unit Leader at Johnson & Johnson MedTech's MONARCH™ robotic platform, demonstrating his capability in complex business environments.
- Strategic Objectives: As Chief Commercial Officer, Miele will define and execute Accuray's global commercialization strategy across sales, marketing, pricing, and market access, aiming to further strengthen the company's commercial impact in over 70 countries worldwide.
- Commitment to Innovation: Accuray is dedicated to improving cancer treatment through continuous innovation, and Miele's addition is expected to drive growth in systems and services sales, particularly in providing value-added solutions to customers, thereby reinforcing the company's market position.
See More
Accuray Q2 2026 Earnings Call Insights
- Transformation Overview: CEO Steve LaNeve highlighted Accuray's comprehensive transformation plan aimed at enhancing operating profitability by approximately $25 million annually through cost structure optimization and organizational realignment, targeting about $12 million in benefits for fiscal 2026.
- Declining Financial Performance: The company reported net revenue of $102.2 million for Q2, down 12% year-over-year, with product revenue at $45 million, a 26% decline, while service revenue showed resilience at $57.2 million, up 4% from the previous year.
- Guidance Reduction: Accuray lowered its fiscal 2026 revenue guidance to $440 million to $450 million and adjusted EBITDA guidance to $22 million to $25 million, reflecting ongoing volatility in China and external pressures such as tariffs.
- Market Risks and Challenges: Management acknowledged that ongoing tariffs and geopolitical instability pose challenges to demand patterns and margin performance, emphasizing the need to focus on consistent execution amid a more challenging global environment, despite strong service revenue and backlog.
See More
Accuray Scheduled to Announce Q2 Earnings on February 4th
- Earnings Announcement Schedule: Accuray (ARAY) is set to release its Q2 earnings on February 4th after market close, with consensus EPS estimate at -$0.11 and revenue forecast at $100.86 million, reflecting a 13.2% year-over-year decline.
- Historical Performance Review: Over the past year, Accuray has only beaten EPS estimates 25% of the time, while it has exceeded revenue estimates 75% of the time, indicating relative stability in revenue but poor EPS performance.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with one downward adjustment, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting market caution regarding the company's future performance.
- Latest Earnings Results: In Q1 2026, Accuray reported a GAAP EPS of -$0.18, missing estimates by $0.12, while revenue of $93.9 million exceeded expectations by $2.55 million, demonstrating resilience in revenue despite ongoing profitability pressures.
See More
Accuray (NASDAQ:ARAY) to Report Q2 FY2026 Financial Results on February 4, 2026
- Earnings Call Schedule: Accuray is set to hold a conference call on February 4, 2026, at 1:30 PM PT (4:30 PM ET) to report its Q2 FY2026 financial results, reflecting the company's commitment to transparency and investor communication.
- Dial-in Information: The call can be accessed via US number 1-833-316-0563 and international number 1-412-317-5747, indicating the company's effort to provide accessible participation channels for global investors, enhancing its appeal to international stakeholders.
- Replay Availability: A replay of the call will be available approximately one hour after its conclusion, with US number 1-855-669-9658 and international number 1-412-317-0088, conference ID 8587254, ensuring that investors who cannot attend live can still access critical information, thereby improving information accessibility.
- Webcast and Replay: The call will be live-streamed on the company's investor relations website and will remain available until the announcement of Q3 FY2026 results, showcasing Accuray's modernization in information dissemination and enhancing investor engagement.
See More
Accuray Initiates Strategic Transformation Plan Expected to Boost Annual Profit by $25 Million
- Strategic Transformation Initiated: Accuray has announced the first phase of its comprehensive strategic transformation plan aimed at enhancing accountability and cost control, with an expected annual profit increase of approximately $25 million, thereby strengthening the company's market competitiveness.
- Organizational Structure Optimization: The plan will streamline the commercial structure, centralize core functions, and elevate global service and product development heads to report directly to the CEO, reallocating resources to support sales growth.
- Layoffs and Outsourcing: The company anticipates a global headcount reduction of about 15%, with expected cost savings of approximately $12 million in fiscal 2026 achieved through layoffs and outsourcing non-core activities, further enhancing profitability.
- Restructuring Charges Expected: Accuray expects to incur around $11 million in restructuring charges during the second, third, and fourth quarters of fiscal 2026, primarily related to workforce reductions and facility consolidations, ensuring the smooth implementation of the transformation plan.
See More
Accuray Appoints New Chief Commercial Officer
- Executive Appointment: Accuray announced the appointment of Paul Miele as Chief Commercial Officer effective April 6, 2026, tasked with leading the global commercial organization to drive transformation and enhance execution, thereby improving market competitiveness.
- Extensive Experience: Miele brings nearly two decades of global commercial leadership experience in the medical technology sector, having previously served as Business Unit Leader at Johnson & Johnson MedTech, where he successfully reversed a revenue decline trend and achieved double-digit annual sales growth.
- Strategic Objectives: As Chief Commercial Officer, Miele will define and execute Accuray's global commercialization strategy across sales, marketing, pricing, and market access, aiming to enhance the company's commercial impact in over 70 countries worldwide.
- Commitment to Innovation: Accuray is dedicated to improving cancer treatment through continuous innovation, and Miele's addition is expected to further drive growth in systems and services sales, particularly in providing value-added solutions to customers.
See More
Accuray Appoints New Chief Commercial Officer
- Executive Appointment: Accuray announced the appointment of Paul Miele as Chief Commercial Officer effective April 6, 2026, tasked with leading the global commercial organization to drive transformation and enhance execution, thereby improving overall commercial performance.
- Extensive Experience: Miele brings nearly two decades of global commercial leadership experience in medical technology, having successfully reversed revenue declines and achieved double-digit annual sales growth as Business Unit Leader at Johnson & Johnson MedTech's MONARCH™ robotic platform, demonstrating his capability in complex business environments.
- Strategic Objectives: As Chief Commercial Officer, Miele will define and execute Accuray's global commercialization strategy across sales, marketing, pricing, and market access, aiming to further strengthen the company's commercial impact in over 70 countries worldwide.
- Commitment to Innovation: Accuray is dedicated to improving cancer treatment through continuous innovation, and Miele's addition is expected to drive growth in systems and services sales, particularly in providing value-added solutions to customers, thereby reinforcing the company's market position.
See More
Accuray Q2 2026 Earnings Call Insights
- Transformation Overview: CEO Steve LaNeve highlighted Accuray's comprehensive transformation plan aimed at enhancing operating profitability by approximately $25 million annually through cost structure optimization and organizational realignment, targeting about $12 million in benefits for fiscal 2026.
- Declining Financial Performance: The company reported net revenue of $102.2 million for Q2, down 12% year-over-year, with product revenue at $45 million, a 26% decline, while service revenue showed resilience at $57.2 million, up 4% from the previous year.
- Guidance Reduction: Accuray lowered its fiscal 2026 revenue guidance to $440 million to $450 million and adjusted EBITDA guidance to $22 million to $25 million, reflecting ongoing volatility in China and external pressures such as tariffs.
- Market Risks and Challenges: Management acknowledged that ongoing tariffs and geopolitical instability pose challenges to demand patterns and margin performance, emphasizing the need to focus on consistent execution amid a more challenging global environment, despite strong service revenue and backlog.
See More
Accuray Scheduled to Announce Q2 Earnings on February 4th
- Earnings Announcement Schedule: Accuray (ARAY) is set to release its Q2 earnings on February 4th after market close, with consensus EPS estimate at -$0.11 and revenue forecast at $100.86 million, reflecting a 13.2% year-over-year decline.
- Historical Performance Review: Over the past year, Accuray has only beaten EPS estimates 25% of the time, while it has exceeded revenue estimates 75% of the time, indicating relative stability in revenue but poor EPS performance.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with one downward adjustment, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting market caution regarding the company's future performance.
- Latest Earnings Results: In Q1 2026, Accuray reported a GAAP EPS of -$0.18, missing estimates by $0.12, while revenue of $93.9 million exceeded expectations by $2.55 million, demonstrating resilience in revenue despite ongoing profitability pressures.
See More
Accuray (NASDAQ:ARAY) to Report Q2 FY2026 Financial Results on February 4, 2026
- Earnings Call Schedule: Accuray is set to hold a conference call on February 4, 2026, at 1:30 PM PT (4:30 PM ET) to report its Q2 FY2026 financial results, reflecting the company's commitment to transparency and investor communication.
- Dial-in Information: The call can be accessed via US number 1-833-316-0563 and international number 1-412-317-5747, indicating the company's effort to provide accessible participation channels for global investors, enhancing its appeal to international stakeholders.
- Replay Availability: A replay of the call will be available approximately one hour after its conclusion, with US number 1-855-669-9658 and international number 1-412-317-0088, conference ID 8587254, ensuring that investors who cannot attend live can still access critical information, thereby improving information accessibility.
- Webcast and Replay: The call will be live-streamed on the company's investor relations website and will remain available until the announcement of Q3 FY2026 results, showcasing Accuray's modernization in information dissemination and enhancing investor engagement.
See More
Accuray Initiates Strategic Transformation Plan Expected to Boost Annual Profit by $25 Million
- Strategic Transformation Initiated: Accuray has announced the first phase of its comprehensive strategic transformation plan aimed at enhancing accountability and cost control, with an expected annual profit increase of approximately $25 million, thereby strengthening the company's market competitiveness.
- Organizational Structure Optimization: The plan will streamline the commercial structure, centralize core functions, and elevate global service and product development heads to report directly to the CEO, reallocating resources to support sales growth.
- Layoffs and Outsourcing: The company anticipates a global headcount reduction of about 15%, with expected cost savings of approximately $12 million in fiscal 2026 achieved through layoffs and outsourcing non-core activities, further enhancing profitability.
- Restructuring Charges Expected: Accuray expects to incur around $11 million in restructuring charges during the second, third, and fourth quarters of fiscal 2026, primarily related to workforce reductions and facility consolidations, ensuring the smooth implementation of the transformation plan.
See More
